Lawsuit filed for Investors in shares of Apyx Medical Corporation (NASDAQ: APYX)

An investor, who purchased shares of Apyx Medical Corporation (NASDAQ: APYX), filed a lawsuit over alleged violations of Federal Securities Laws by Apyx Medical Corporation.

Investors who purchased shares of Apyx Medical Corporation (NASDAQ: APYX) have certain options and for certain investors are short and strict deadlines running. Deadline: August 5, 2022. NASDAQ: APYX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Clearwater FL based Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. On March 14, 2022, Apyx Medical Corporation disclosed that the U.S. Food and Drug Administration ("FDA") would be posting a Medical Device Safety Communication ("MDSC") related to the Company's Advanced Energy Products. The Company further disclosed that "[b]ased on our initial interactions with the FDA, we believe the Agency's MDSC will pertain to the use of our Advanced Energy products outside of their FDA-cleared indication for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures." Shares of Apyx Medical Corporation (NASDAQ: APYX) declined from $11.18 per share on March 1, 2022, to as low as $4.14 per share on April 27, 2022.

The plaintiff claims that between May 12, 2021 and March 11, 2022, the Defendants failed to disclose to investors that a significant number of Apyx's Advanced Energy products were used for off-label indications, that such off-label uses led to an increase in the number of medical device reports filed by Apyx Medical Corporation reporting serious adverse events, that, as a result, the Company was reasonably likely to incur regulatory scrutiny, that, as a result of the foregoing, the Company's financial results would be adversely impacted, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis

Those who purchased shares of Apyx Medical Corporation (NASDAQ: APYX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.